IL17A and neoplasm: In BRAF V600-mutated melanomas, high levels of IL-17 gene expression supported the anti-tumor effects of dual ICI with anti-PD-L1 and anti-CTLA-4, but not with single anti-CTLA-4 or anti-PD-1 therapy (169).